Genetics of Mycobacterium tuberculosis adaptation to the macrophage phagosome
Genetics of Mycobacterium tuberculosis adaptation to the macrophage phagosome
批准号:
7777843
负责人:
Robert B Abramovitch
金额:
$5.22万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-07-01 至 2012-06-30
关键词:
AdultAmericanAntibiotic TherapyBiochemistryBiologyCause of DeathCommunicable DiseasesCuesDevelopmentDiseaseEarly EndosomeEnvironmentEvolutionExposure toFlow CytometryFluorescenceFoundationsGene ExpressionGenesGeneticGenetic ScreeningGoalsGreen Fluorescent ProteinsGrowthHealthHumanIn VitroLesionLifeLysosomesMicrobeMolecular ProfilingMulti-Drug ResistanceMutagenesisMycobacterium tuberculosisNitrogenPathogenesisPhagocytosisPhagosomesPharmaceutical PreparationsPharmacotherapyPhenotypeRelative (related person)ReporterResearchResourcesSignal TransductionSorting - Cell MovementSpecificityStimulusTechniquesTravelTuberculosisUrsidae FamilyVaccinesVacuoleWorkbasefield studyfunctional genomicsin vivointerestkillingsloss of functionmacrophagemutantnitrosative stressnovelpathogenpromoterpublic health relevancereactive oxygen intermediateresearch studyresistant strainresponsesuccess
中文摘要
描述(申请人提供):结核分枝杆菌(Mtb)是一种细胞内病原体,其成功的关键是能够在巨噬细胞吞噬体中存活。对于许多微生物来说,巨噬细胞的吞噬作用是由于转移到溶酶体或暴露于氧化或亚硝化应激而杀死的。结核分枝杆菌通过阻止吞噬体成熟并驻留在与早期核内体相似的相对安全的液泡中来避免这些杀伤机制。本应用程序的目标是利用功能基因组技术探索结核分枝杆菌适应巨噬细胞吞噬体的机制,包括:巨噬细胞内生长的结核分枝杆菌转录谱和用于基因筛选的新型转座子诱变方法,以发现适应吞噬体的突变体缺陷。该应用的具体目的是:1)开发对体外和体内特定环境线索作出反应的荧光结核分枝杆菌报告菌株。为此,吞噬体刺激调控的基因将通过基于微阵列的细胞内和培养中生长的结核分枝杆菌转录谱来鉴定。在体外和体内受特定刺激调控的基因启动子将用于在结核分枝杆菌中表达绿色荧光蛋白。2)利用基于流式细胞术的遗传筛选技术鉴定对吞噬体环境反应改变的结核分枝杆菌突变体。在这个屏幕上,Mtb报告菌株将被转座子诱变并暴露于感兴趣的刺激。与野生型菌株相比,荧光较少的突变体将通过基于流式细胞术的分选进行富集。这些丧失功能的突变体可能在与感知或调节对刺激的反应相关的基因中有损伤。这项工作将确定结核分枝杆菌用来适应巨噬细胞吞噬体的基因。其中一些基因将成为新药或疫苗策略的靶点。此外,胞内结核分枝杆菌基因表达的转录谱将成为微生物学家在不同研究领域的宝贵资源。公共卫生相关性:结核分枝杆菌是人类结核病的病原体,是一种需要深入研究的微生物。在世界范围内,它是一种传染病导致死亡的主要原因,成人没有有效的疫苗,由于长期抗生素治疗的依从性低,目前的药物治疗正在导致耐多药菌株的演变。结核病是一种高度传染性的空气传播疾病,鉴于全球旅行相对容易,世界上任何地方的高结核病发病率都对所有美国人的健康构成严重威胁。如果我们要发现和实施新的治疗方法或疫苗,对结核病生物学更全面的了解是必不可少的。
英文摘要
DESCRIPTION (provided by applicant): Mycobacterium tuberculosis (Mtb) is an intracellular pathogen and a key to its success is the ability to survive in the macrophage phagosome. For many microbes, phagocytosis by a macrophage kills, due to transfer to the lysosome or exposure to oxidative or nitrosative stresses. Mtb avoids these killing mechanisms by arresting phagosome maturation and residing in a relatively safe vacuole that bears similarities to the early endosome. The goal of this application is to explore the mechanisms of Mtb adaptation to the macrophage phagosome using functional genomic techniques including: transcriptional profiling of Mtb growing inside macrophages and novel transposon mutagenesis approaches for genetic screens to discover mutants defective in adaptation to the phagosome. The specific aims of this application are: 1) the development of fluorescent Mtb reporter strains that respond to specific environmental cues in vitro and in vivo. For this aim, genes regulated by phagosomal stimuli will be identified by microarray-based transcriptional profiling of Mtb growing intracellularly and in culture. Promoters from genes regulated by a specific stimulus both in vitro and in vivo will be used to express green fluorescent protein in Mtb. 2) Identification of Mtb mutants that are altered in their response to the phagosomal environment using a flow cytometry-based genetic screen. In this screen, the Mtb reporter strains will be transposon mutagenized and exposed to a stimulus of interest. Mutants with less fluorescence as compared to the wild type strain will be enriched by flow cytometry-based sorting. These loss-of-function mutants may have lesions in genes associated with sensing or modulating a response to the stimulus. This work will identify genes that Mtb uses to adapt to the macrophage phagosome. Some of these genes will represent targets for novel drugs or vaccine strategies. Additionally, the transcriptional profiles of intracellular Mtb gene expression will be a valuable resource for microbiologists in diverse fields of study. PUBLIC HEALTH RELEVANCE: Mycobacterium tuberculosis, the causative agent of tuberculosis in humans, is a microbe that requires intensive study. Worldwide, it is a leading cause of death by an infectious disease, there is no effective vaccine for adults, and current drug therapies are leading to the evolution of multidrug-resistant strains because of low compliance to prolonged antibiotic treatments. Tuberculosis is a highly infectious, airborne disease and given the relative ease of global travel, high rates of tuberculosis anywhere in the world represents a serious threat to the health of all Americans. A more complete understanding of tuberculosis biology is essential if we are to discover and implement novel therapies or vaccines.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Chemical biology studies of MmpL3 inhibition and resistance in mycobacteria
-
批准号:10734240
-
项目类别:
-
资助金额:$75.9万
-
财政年份:2023
-
负责人:Robert B Abramovitch
-
依托单位:
Chemical genetics of M. tuberculosis DosRST signaling and persistence
-
批准号:10119676
-
项目类别:
-
资助金额:$71.8万
-
财政年份:2020
-
负责人:Robert B Abramovitch
-
依托单位:
Chemical genetics of M. tuberculosis DosRST signaling and persistence
-
批准号:10470823
-
项目类别:
-
资助金额:$73.04万
-
财政年份:2020
-
负责人:Robert B Abramovitch
-
依托单位:
Chemical genetics of M. tuberculosis DosRST signaling and persistence
-
批准号:10267727
-
项目类别:
-
资助金额:$72.59万
-
财政年份:2020
-
负责人:Robert B Abramovitch
-
依托单位:
Characterizing new M. tuberculosis inhibitors discovered in the Molecular Libraries Small Molecule Repository
-
批准号:10029703
-
项目类别:
-
资助金额:$7.45万
-
财政年份:2020
-
负责人:Robert B Abramovitch
-
依托单位:
Mechanisms of Mycobacterium Tuberculosis pH-driven Adaptation
-
批准号:9024246
-
项目类别:
-
资助金额:$39.28万
-
财政年份:2015
-
负责人:Robert B Abramovitch
-
依托单位:
Screening for inhibitors of M. tuberculosis persistence-related lipid metabolism
-
批准号:8509336
-
项目类别:
-
资助金额:$19.01万
-
财政年份:2013
-
负责人:Robert B Abramovitch
-
依托单位:
Genetics of Mycobacterium tuberculosis adaptation to the macrophage phagosome
-
批准号:8081743
-
项目类别:
-
资助金额:$2.84万
-
财政年份:2009
-
负责人:Robert B Abramovitch
-
依托单位:
海外基金